SCHEMBL2394352

SCHEMBL2394352

COC(=O)c1ccc(NC(=O)c2cc3c4c(c2)CCCC4(C)CCC3)cc1OC

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.45
RAB9A P51151 4/20 0.45
KMT2A Q03164 4/20 0.45
MEN1 O00255 3/20 0.45
ALDH1A1 P00352 2/20 0.42
ALOX5 P09917 1/20 0.42
KDM4E B2RXH2 1/20 0.42
GAA P10253 1/20 0.42
DHODH Q02127 2/20 0.42
LMNA P02545 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
TP53 P04637 1/20 0.41
HSD11B1 P28845 1/20 0.41
SETD7 Q8WTS6 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
MAPK14 Q16539 1/20 0.39
MAPT P10636 1/20 0.39
RARA P10276 1/20 0.39
RARB P10826 1/20 0.39
RARG P13631 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2398289 0.92 NPC1 (0.45) NPC1RAB9AKMT2AMEN1ALDH1A1
SCHEMBL2390930 0.88 SMN1; SMN2 (0.50) NPC1RAB9AKMT2AALDH1A1KDM4E
SCHEMBL2394316 0.87 RARA (0.46) NPC1RAB9AKMT2AMEN1ALDH1A1
SCHEMBL2393263 0.87 SMN1; SMN2 (0.43) NPC1RAB9AKMT2AMEN1ALDH1A1
SCHEMBL2394353 0.84 NPC1 (0.50) NPC1RAB9AKMT2AMEN1ALDH1A1
SCHEMBL2397091 0.82 NPC1 (0.46) NPC1RAB9AKMT2AMEN1ALDH1A1
SCHEMBL2395776 0.81 MCHR1 (0.46) NPC1RAB9AKMT2AMEN1ALDH1A1
SCHEMBL2392941 0.79 KMT2A (0.54) NPC1RAB9AKMT2AMEN1ALDH1A1
SCHEMBL2394694 0.79 MAPKAPK2 (0.44) NPC1RAB9AKMT2AMEN1SMN1; SMN2
SCHEMBL2394731 0.78 KDM4E (0.48) NPC1RAB9AKMT2AMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2189443-B1 TRICYCLIC AMIDE COMPOUND RES FOUND ITSUU LAB (JP) 2013-10-23 EP disclosed
US-8232300-B2 Tricyclic amide compound RESEARCH FOUNDATION ITSUU LABORATORY (JP) 2012-07-31 US disclosed
US-8232300-B2 Tricyclic amide compound RESEARCH FOUNDATION ITSUU LABORATORY (JP) 2012-07-31 US disclosed
US-8232300-B2 Tricyclic amide compound RESEARCH FOUNDATION ITSUU LABORATORY (JP) 2012-07-31 US disclosed
US-20110213157-A1 TRICYCLIC AMIDE COMPOUND RESEARCH FOUNDATION ITSUU LABORATORY (JP) 2011-09-01 US disclosed
US-20110213157-A1 TRICYCLIC AMIDE COMPOUND RESEARCH FOUNDATION ITSUU LABORATORY (JP) 2011-09-01 US disclosed
US-20110213157-A1 TRICYCLIC AMIDE COMPOUND RESEARCH FOUNDATION ITSUU LABORATORY (JP) 2011-09-01 US disclosed
EP-2189443-A1 TRICYCLIC AMIDE COMPOUND Research Foundation Itsuu Laboratory (JP) 2010-05-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110213157-A1 TRICYCLIC AMIDE COMPOUND RXRA, RXRB, RXRG NPC1 905/4885RAB9A 1612/4885KMT2A 1560/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.